Study targets COVID-19 variant antibody effectiveness after Moderna vaccination
Researchers found that the effectiveness of the vaccine held for about 6 months in most adults, but began to be less effective at that time point.
Related Articles
Ophthalmologists embrace potential of clinically tested nutraceuticals for dry eye disease
Look beyond isolated treatment of the eye to address systemic factors.
Comparing ChatGPT 3.5, Microsoft Bing, and Google Gemini in diagnosing cases of neuro-ophthalmology
A brief analysis showed that ChatGPT 3.5 performed better.
Using extracellular vesicles in the treatment of ocular diseases
Shift could lead to changes in the current management of retinal diseases
The evolving role of vitreosurgical simulators in surgical training
Need to eliminate errors results in optimization of training of novice surgeons.
Study evaluates the potential correlation of ultra-processed food consumption and increased glaucoma incidence
UPFs include fast food, energy drinks and soda, sweets such as chocolates and candies and much more.
The role of multimodal imaging in ocular trauma
Closed globe ocular injury often leads to macular pathology
What’s Your WhEYE? A conversation with Paul Badawi, CEO of Sight Sciences
Paul Badawi, co-founder and CEO of Sight Sciences, sits down with host Neda Shamie, MD, to discuss his journey into the field of eye care,…
Ophthalmologists embrace potential of clinically tested nutraceuticals for dry eye disease
Look beyond isolated treatment of the eye to address systemic factors.
Efficacy, safety of switching to latanoprostene bunod 0.024% in patients with OAG and OHT
The switch may produce an additional 25% IOP reduction in mild to moderate forms of disease
Treatment challenges in patients with nAMD
David Eichenbaum, MD, discusses his experiences with aflibercept, faricimab.